CPHI 2024: AB-Biotics spots targeted probiotic solutions as next frontier
08 Nov 2024 | AB-BIOTICS
Miquel Bonachera, co-founder and executive director of AB-Biotics, detailed how clinical research on biotics and their health impacts has evolved, from proving probiotics’ safety to developing more targeted solutions in recent years. AB-Biotics has taken a “bottom-up” approach since its conception — identifying a strain based on its mechanism of action and then clinically demonstrating the strain’s health effect. The company has also developed products for oral and cardiovascular health.
More videos
